Fibronox spun out from University of Arizona’s College of Medicine – Tucson in 2017 to deliver Nox4-inhibiting drugs for fibrotic disorders including lung fibrosis.
Tech Launch Arizona (TLA), the tech transfer office of University of Arizona, has formally unveiled a US-based spinout called Fibronox to design small molecule drugs for fibrotic disorders.
Founded in 2017, Fibronox develops drugs for progressive scar tissue deposits that can chronically arise in areas of the body including the lungs, liver and intestines. These potentially fatal conditions are collectively known as fibrotic disorders.
The spinout’s initial approach targets mechanisms affecting the regulation of NADPH oxidase 4 (Nox4)…
